A groundbreaking development in AI has achieved 86% accuracy in predicting the success of clinical trials, addressing the high failure rate of traditional methods. By optimizing trial designs, the company significantly increased target populations and reduced costs and durations, ultimately enhancing patient outcomes. With new funding, the startup aims to expand its innovative solutions, promising a transformative impact on drug development and healthcare efficiency.
